Rezolute, Inc. SEC filings RZLT
Rezolute, Inc. has 755 filings in SEC EDGAR's recent list, going back to May 17, 2011. Its latest annual report, Form 10-K, was filed on Sep 24, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 12, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (regulation fd disclosure). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Feb 12, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 10-Q | Quarterly report | Feb 12, 2025 | Dec 31, 2024 |
| 10-Q | Quarterly report | Nov 7, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | Feb 13, 2024 | Dec 31, 2023 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 10-Q | Quarterly report | Feb 10, 2023 | Dec 31, 2022 |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 10-Q | Quarterly report | Feb 9, 2022 | Dec 31, 2021 |
| 10-Q | Quarterly report | Nov 12, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | May 17, 2021 | Mar 31, 2021 |
| 10-Q | Quarterly report | Feb 10, 2021 | Dec 31, 2020 |
| 10-Q | Quarterly report | Nov 12, 2020 | Sep 30, 2020 |
| 10-Q | Quarterly report | May 14, 2020 | Mar 31, 2020 |
| 10-Q | Quarterly report | Feb 12, 2020 | Dec 31, 2019 |
| 10-Q | Quarterly report | Nov 14, 2019 | Sep 30, 2019 |
| 10-Q | Quarterly report | May 10, 2019 | Mar 31, 2019 |
| 10-Q | Quarterly report | Feb 14, 2019 | Dec 31, 2018 |
| 10-Q | Quarterly report | Dec 14, 2018 | Sep 30, 2018 |
| 10-Q | Quarterly report | May 15, 2018 | Mar 31, 2018 |
| 10-Q | Quarterly report | Feb 14, 2018 | Dec 31, 2017 |
| 10-Q | Quarterly report | Nov 14, 2017 | Sep 30, 2017 |
| 10-Q | Quarterly report | May 15, 2017 | Mar 31, 2017 |
| 10-Q | Quarterly report | Feb 2, 2017 | Dec 31, 2016 |
| 10-Q | Quarterly report | Nov 14, 2016 | Sep 30, 2016 |
| 10-Q | Quarterly report | May 16, 2016 | Mar 31, 2016 |
| 10-Q | Quarterly report | Feb 16, 2016 | Dec 31, 2015 |
| 10-Q | Quarterly report | Nov 16, 2015 | Sep 30, 2015 |
| 10-Q | Quarterly report | May 15, 2015 | Mar 31, 2015 |
| 10-Q | Quarterly report | Feb 17, 2015 | Dec 31, 2014 |
| 10-Q | Quarterly report | Nov 12, 2014 | Sep 30, 2014 |
| 10-Q | Quarterly report | May 14, 2014 | Mar 31, 2014 |
| 10-Q | Quarterly report | Feb 13, 2014 | Dec 31, 2013 |
| 10-Q | Quarterly report | Nov 12, 2013 | Sep 30, 2013 |
| 10-Q | Quarterly report | May 15, 2013 | Mar 31, 2013 |
| 10-Q | Quarterly report | Feb 14, 2013 | Dec 31, 2012 |
| 10-Q | Quarterly report | Nov 19, 2012 | Sep 30, 2012 |
| 10-Q | Quarterly report | May 15, 2012 | Mar 31, 2012 |
| 10-Q | Quarterly report | Feb 14, 2012 | Dec 31, 2011 |
| 10-Q/A | Amended quarterly report | Dec 13, 2011 | Sep 30, 2011 |
| 10-Q | Quarterly report | Nov 14, 2011 | Sep 30, 2011 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RZLT (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Redwood City, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1509261
- Former names
- AntriaBio, Inc. (until Dec 7, 2017); FITS MY STYLE INC (until Jan 11, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.